Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Zentalis Pharmaceuticals, Inc. (ZNTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2023 8-K Investor presentation
Docs: "Corporate Presentation August 2023 Nasdaq: ZNTL Exhibit 99.1 2 Forward Looking Statement and Disclaimer Zentalis Pharmaceuticals, Inc."
08/09/2023 8-K Quarterly results
Docs: "Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing"
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT TO"
05/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin"
05/10/2023 8-K Quarterly results
Docs: "Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023"
04/26/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
02/13/2023 8-K Quarterly results
01/09/2023 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2022 8-K Investor presentation, Quarterly results
Docs: "Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson",
"C O R P O R AT E P R E S E N TAT I O N A"
07/22/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "1271 Avenue of the Americas New York, New York 10020-1401",
"Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells",
"SECURITIES PURCHASE AGREEMENT"
04/11/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts"
04/11/2022 8-K/A Investor presentation
04/08/2022 8-K Regulation FD Disclosure, Other Events  Interactive Data
Docs: "Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts",
"A A C R 2 0 2 2 I"
02/24/2022 8-K Quarterly results
11/17/2021 8-K Other Events  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initiated a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma"
08/12/2021 8-K Quarterly results
07/01/2021 8-K Other Events  Interactive Data
Docs: "3,100,000 Shares ZENTALIS PHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT",
"Letter re: Registration Statement on Form S-3"
06/28/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy